We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

Pfizer sells entire Haleon stake for $3.24 billion Drugmaker ... according to three people familiar with the matter. The U.S. Food and Drug Administration has proposed to remove oral phenylephrine ...

(RTTNews) - Pfizer Inc. (PFE) announced the sales of around 618 million ordinary shares in Haleon plc (HLN) at a price of 385 pence or about $5.01 per Ordinary Share for gross proceeds of ...